Pivotal Life Sciences — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Avalyn Pharma Incavalynpharma.cominNASDAQ: AVLNSep 2023 · $175M
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+7 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.